BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26249119)

  • 1. Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
    Colleoni M; Munzone E
    Breast; 2015 Nov; 24 Suppl 2():S11-4. PubMed ID: 26249119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
    J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
    Francis PA
    Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
    Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
    Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
    Azim HA; Davidson NE; Ruddy KJ
    Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
    Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
    J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.
    Abbas W; Rao RR
    Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
    Cheung KL; Agrawal A; Folkerd E; Dowsett M; Robertson JF; Winterbottom L
    Eur J Cancer; 2010 Nov; 46(16):2936-42. PubMed ID: 20832294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
    Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
    Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
    Ribi K; Luo W; Bernhard J; Francis PA; Burstein HJ; Ciruelos E; Bellet M; Pavesi L; Lluch A; Visini M; Parmar V; Tondini C; Kerbrat P; Perelló A; Neven P; Torres R; Lombardi D; Puglisi F; Karlsson P; Ruhstaller T; Colleoni M; Coates AS; Goldhirsch A; Price KN; Gelber RD; Regan MM; Fleming GF
    J Clin Oncol; 2016 May; 34(14):1601-10. PubMed ID: 27022111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
    Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC
    BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.